RxDoctor Payments Data

Nathan Singh, MD

Medical Oncology · Saint Louis, MONPI 1114362795

Payments from drug & device makers

What this record shows

This record is dominated by grants: $18,182 of the $18,319 with a category attached, or 99.2%. Genentech, Inc. accounts for 99.2% of it on its own, with 2 other manufacturers making up the rest.

$18,319in general payments, 2019–2025

Across 3 payments — averaging $6106.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$18K
  • Gilead$125
  • AbbVie$13
$180,000in research payments, 2019–2025

Across 2 payments — averaging $90,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$180K

What the payments were for

  • Grants$18,18299%
  • Food & beverage$1381%

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.1$18,182
Gilead1$125
AbbVie1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,319 in reported general payments places this provider in the 70th percentile of 144 medical oncology providers in Missouri.

See all medical oncology providers in Missouri →

Medicare billing

Part B allowed, 2024
$18,121
Medicare patients
61
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Saint Louis

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →